Pharma firm Anges and Osaka University to begin testing coronavirus vaccine on animals
24/03/2020 24:16
TOKYO, March 24 (Reuters) - Japanese biopharmaceutical firm
Anges Inc 4563.T said on Tuesday it and partner Osaka
University had completed development of a prophylactic DNA
vaccine against the new coronavirus and that it would begin
testing it in animals soon.
Shares of Anges were untraded with a glut of buy orders in
early morning.
There are now more than 350,000 cases of coronavirus
infections globally and over 15,000 deaths resulting from the
disease it causes, called COVID-19.
(Reporting by Chang-Ran Kim; Editing by Kim Coghill)
((ran.kim@thomsonreuters.com; +81-3-4563-2740;))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001